Summary:
In this prospective study, we assessed the incidence of central venous catheter (CVC)-related thrombosis in haematopoietic stem cell transplant (HSCT) recipients. We determined the contribution of inherited prothrombotic abnormalities in blood coagulation to CVC-related thrombosis in these patients. The study was conducted between May 2002 and September 2004. CVCs were externalized, nontunneled, polyurethane double lumen catheters. Before catheter insertion, laboratory prothrombotic markers included factor V Leiden, the prothrombin gene Gly20210A mutation, plasma antithrombin levels, and protein C and S activity. All patients were systematically examined by ultrasonography just before, or <24 h after, catheter removal, and in case of clinical signs of thrombosis. A total of 171 patients were included during the 28-month study period. Five (2.9%) and three (1.7%) patients had evidence of protein C and protein S deficiency, respectively. Only one patient had an antithrombin deficiency (0.6%). In total, 10 patients (5.8%) were heterozygous for the factor V Leiden mutation, and one patient had heterezygous prothrombin G20210A mutation (0.6%). We observed a CVC-related thrombosis in 13 patients (7.6%). Thrombosis was diagnosed in four out of 20 patients (20%) with a inherited prothrombotic abnormality compared to nine of 151 patients (6%) who did not have a thrombophilic marker (relative risk 3.3 CI 95% 1.1–9.9). Our results suggest that inherited prothrombotic abnormalities contribute substantially to CVC-related thrombosis in HSCT recipients. In view of physicians’ reluctance to prescribe prophylactic anticoagulant treatment in these patients, a priori determination of inherited prothrombotic abnormalities may form a basis to guide these treatment decisions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Madero L, Ruano D, Villa M et al. Non-tunnelled catheters in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 17: 87–89.
Kumagai T, Sakamaki H, Tanikawa S et al. Utility and safety of Hickman catheters for venous access after bone marrow transplantation. Intern Med 1998; 37: 286–291.
Male C, Chait P, Andrew M et al. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 2003; 101: 4273–4278.
McGee DC, Gould MK . Preventing complications of central venous catheterization. N Engl J Med 2003; 348: 1123–1133.
Monreal M, Raventos A, Lerma R et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines – a prospective study. Thromb Haemost 1994; 72: 548–550.
Ross AH, Griffith CD, Anderson JR, Grieve DC . Thromboembolic complications with silicone elastomer subclavian catheters. J Parenter Enteral Nutr 1982; 6: 61–63.
Bozzetti F, Scarpa D, Terno G et al. Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients. J Parenter Enteral Nutr 1983; 7: 560–562.
Haire WD, Lieberman RP, Edney J et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990; 66: 900–908.
Conlan MG, Haire WD, Lieberman RP et al. Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 1991; 7: 235–240.
Boraks P, Scale J, Price J et al. Prevention of central venous catheter-associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101: 483–486.
Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism- pooled analysis of 8 case–control studies including 2310 cases and 3204 controls. Thromb Haemost 2001; 86: 809–816.
Fijnheer R, Paijmans B, Verdonck LF et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118: 267–270.
Bertina RM, Koeleman BP, Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.
Poort SR, Rosendaal FR, Reitsma PH, Bertina RM . A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–3703.
Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353–2358.
Seldinger S . Catheter replacement of the needle in percutaneous arteriography: a new technique. Acta Radiol 1953; 39: 368–376.
Koksoy C, Kuzu A, Kutlay J et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995; 50: 687–689.
Prandoni P, Polistena P, Bernardi E et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997; 157: 57–62.
Patel MC, Berman LH, Moss HA et al. Subclavian and internal jugular veins at Doppler US: abnormal cardiac pulsatility and respiratory phasicity as a predictor of complete central occlusion. Radiology 1999; 211: 579–583.
Ratcliffe M, Broadfoot C, Davidson M et al. Thrombosis, markers of thrombotic risk, indwelling of central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol 1999; 21: 353–357.
Riordan M, Weiden PL . Factor V leiden mutations does not account for central venous catheter-related thrombosis. Am J Hematol 1998; 58: 150–152.
van Rooden CJ, Rosendaal FR, Meinders AE et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89: 201–206.
Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423–428.
Monreal M, Alastrue A, Rull M et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251–253.
Abdelkefi A, Ben Othman T, Kammoun L et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. Throm Haemost 2004; 92: 654–661.
van Rooden CJ, Monraats PS, Kettenis I et al. Low physician compliance of prescribing anticoagulant prophylaxis in patients with solid tumor or haematological malignancies and central vein catheters. J Thromb Hemost 2003; 1: 1842–1843.
Carr KM, Rabinowitz I . Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol 2000; 18: 3665–3667.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abdelkefi, A., Ben Romdhane, N., Kriaa, A. et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant 36, 885–889 (2005). https://doi.org/10.1038/sj.bmt.1705156
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705156